IRLAB’s Phase IIb/III Study in Parkinson’s disease to Target Good ON

IRLAB’s Phase IIb/III Study in Parkinson’s disease to Target Good ON
IRLAB's clinical Phase IIb/III study with the drug candidate mesdopetam (IRL790) in development for the treatment of levodopa induced dyskinesia (LIDs) in Parkinson's disease, will have a study design ... read more
Source: Bing NewsPublished on 2020-06-03